Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday

Recursion Pharmaceuticals (RXRX -15.70%) didn't have a fine start to the working week on Monday, at least as far as its stock was concerned. Investors traded out of it following the clinical-stage biotech's first-quarter earnings release and business update, and the share price was down by 15% in mid-session trading. The S&P 500 index was doing comparatively better, with a 0.3% decline. Light revenue and a deepening net lossFor the quarter, Recursion -- which although a clinical-stage company earns some coi ...